{"id":"NCT01755689","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults","officialTitle":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine 134612 With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults at 9-25 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01-11","primaryCompletion":"2014-04-29","completion":"2014-04-29","firstPosted":"2012-12-24","resultsPosted":"2018-07-03","lastUpdate":"2018-07-03"},"enrollment":1300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal vaccine GSK134612","otherNames":["Nimenrix®"]},{"type":"BIOLOGICAL","name":"Cervarix®","otherNames":[]},{"type":"BIOLOGICAL","name":"Boostrix®","otherNames":[]}],"arms":[{"label":"Nimenrix+Cervarix (1,2,7-Month) Group","type":"EXPERIMENTAL"},{"label":"Nimenrix+Cervarix (0,1,6-Month) Group","type":"EXPERIMENTAL"},{"label":"Cervarix Group","type":"EXPERIMENTAL"},{"label":"Nimenrix+Cervarix+Boostrix Group","type":"EXPERIMENTAL"},{"label":"Boostrix+Cervarix Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate safety and immunogenicity of GSK Biologicals' meningococcal vaccine GSK134612 (MenACWY-TT) co-administered with Cervarix as compared to MenACWY-TT and Cervarix administered alone and the co-administration of MenACWY-TT with Cervarix and Boostrix as compared to MenACWY-TT administered alone and Cervarix co-administered with Boostrix.","primaryOutcome":{"measure":"Anti-Meningitis Antibody Titers by Serum Bactericidal Assay Using Rabbit Complement (rSBA)","timeFrame":"At one month after vaccination with Nimenrix (Month 1)","effectByArm":[{"arm":"Nimenrix+Cervarix (1,2,7-Month) Group","deltaMin":5517.1,"sd":null},{"arm":"Nimenrix+Cervarix (0,1,6-Month) Group","deltaMin":5523.5,"sd":null},{"arm":"Nimenrix+Cervarix+Boostrix Group","deltaMin":4649.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"9 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":30},"locations":{"siteCount":3,"countries":["Dominican Republic","Estonia","Thailand"]},"refs":{"pmids":["29789243"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":259},"commonTop":["Pain","Fatigue","Headache","Myalgia","Erythema"]}}